Objective: To evaluate the impact and cost-effectiveness of needle-syringe programs (NSPs) with respect to HIV and hepatitis C virus (HCV) infections among Australian injecting drug users (IDUs).
Introduction
In many parts of the world, the sharing of injecting equipment, including needle-syringes, among injecting drug users (IDUs) is a major mode of transmission of blood-borne viruses such as HIV and hepatitis C virus (HCV) [1, 2] . To reduce the spread of HIV and HCV infections through needle-syringe sharing, Australia introduced needle-syringe programs (NSPs) in 1986 [3] . HIV prevalence among IDUs in Australia has since remained relatively low and stable at approximately 1% [4] ; however, HCV prevalence has remained relatively high at 50-70% [4] . At present, there are more than 3000 NSP sites across Australia, comprising primary and Globally, there are significant differences in HIV epidemics among IDUs. Ecological studies suggest that where NSPs are not easily accessible, HIV prevalence tends to be substantially higher than in settings where NSPs are available and easily accessible. For example, Hurley et al. [5] identified studies which estimated HIV seroprevalence among IDUs in the United States between 1988 and 1993 and estimated an average annual increase in HIV prevalence of 5.9% in cities without NSPs, whereas seroprevalence decreased by an average of 5.8% per year in cities with NSPs. HIV acquisition among IDUs has been shown to be significantly associated with nonuse of NSPs [6, 7] .
In this study, we aimed to, first, estimate the likely impact of NSPs in preventing HIV and HCV transmission at the population level in Australia over the period 2000-2010, and second, estimate the cost utility of NSPs. To estimate the effect of an intervention, one could compare epidemiological indicators in the population of interest with a relevant control population. Another approach to impact evaluation is to compare observed conditions with a counterfactual scenario described by an epidemiological model. The counterfactual is intended to represent what the epidemics would look like in the absence of the intervention. The epidemiological model is used to generate an estimate for the counterfactual in lieu of a 'real' comparison case. Here, we examined available empirical data to inform assumptions about the counterfactual with respect to the dominant behavioral factor of HIV and HCV transmission, namely, extent of receptive syringe sharing (RSS). We developed an epidemiological model, which we then calibrated to reflect the historical HIV and HCV epidemics among Australian IDUs. This model was then compared with the epidemics that would have been expected according to the counterfactual conditions.
Methods
Relationship between needle-syringe distribution and receptive syringe sharing NSPs aim to reduce the rate of RSS. We examined the relationship between NSP distribution and reported levels of RSS with others in the past month. The numbers of syringes distributed across Australia through NSPs were collected from each Australian state and territory health department for the period 1993-2008 [8] . Syringe distribution in Australia has increased over time (Fig. 1a,  circles) . Currently, approximately 200 syringes are distributed per IDU per year on average, based on an estimated IDU population size of 170 000 [8] . The frequency of RSS among IDUs has been estimated annually since 1995 through the Australian Needle and Syringe Program Survey (ANSPS), a serial cross-sectional seroprevalence survey of IDUs attending NSPs throughout Australia [4, 9] . Over the period 1995-1999, reported prevalence of RSS decreased from 31 to 17% but has since remained steady [4] . During 2000-2010, levels of pharmacy purchasing of needle syringes (Fig. 1a,  rectangles) have been relatively constant despite large increases in the distribution of syringes from NSPs (Fig. 1a, triangles) ; therefore, we assume that increases or decreases in NSP distribution are not offset by changes in pharmacy purchasing.
We also collated data on RSS among Australian IDUs from other surveys conducted during 1970-1995 which are comparable to data from the ANSPS. Four studies were identified which also reported on proportions of surveyed IDU populations who receptively shared in the last month: 27% in Sydney [10] and 32% in Perth [11] in year 1993, 37% in Melbourne [12] during 1990-1995 and 27% in Perth [13] in 1995, corresponding with an estimated NSP distribution of 39 and 48 syringes per IDU per year in year 1993 and 1995 [14] . In Fig. 1b we presented the relationship between RSS and NSP distribution of needle syringes for years in which both RSS prevalence and syringe distribution data are available [10] [11] [12] [13] . In comparison to data presented in Fig. 1b , it has been estimated that RSS levels in the 1970s and 1980s, with no or limited NSP coverage, could have been 70-90% among groups of IDUs [15] [16] [17] . However, considering the impact that increased awareness of blood-borne infections would likely have had on-risk behaviors, we assumed that RSS prevalence would be 25-50% in the absence of NSPs during 2000-2010 (Fig. 1b) . For the counterfactual scenario we assumed that parameters other than RSS would remain unchanged.
Model
A mathematical model was developed to describe HIV and HCV transmission, the distribution of the IDU population across health states over time and the associated healthcare costs under actual conditions and according to the counterfactual scenario. Full details of the model are provided in the Appendix, http:// links.lww.com/QAD/A245. Briefly, the model consists of a number of linked subpopulations ('compartments'), categorized by infection, diagnosis, disease progression (in terms of CD4 categories for HIV and stages of fibrosis and clinical states for HCV) and treatment states, as shown in Fig. 2 . IDUs who are successfully treated for HCV become susceptible again, and can thus be reinfected. The rates of transition between compartments are defined by parameters based on available data. These can be divided into biological parameters (including HIV and HCV transmission probabilities, HIV-related and HCV-related death rates, transition probabilities and treatment effectiveness) and behavioral parameters (including the transport and vending machines). We also derived estimates of average annual costs for different HIV and HCV health states using published literature and local data (estimated from activity-based analysis and national databases) [8] . The annual healthcare cost for a person living with HIV varied from A$1523-2731 (excluding antiretroviral drugs), depending on the health state. In addition, the annual cost of antiretroviral therapy (ART) was estimated to be A$14 613 for first-line therapy, A$15 178 for second-line and A$27 776 for subsequent lines of ART per person per year. The annual healthcare cost for a person living with HCV was estimated to range A$288-114 411, from early HCV infection to liver transplantation, respectively. The unit costs of hospital admission were estimated by searching health department data on the frequency and proportions of admission to hospital with different health states of HCV and HIV [18] and then deriving a weighted average cost per admission in a health state using cost weights for admission to an Australian public hospital [19] . Outpatient items were valued from the Australian Medicare Benefits Schedule [20] and Pharmaceutical Benefits Scheme [21] . Client costs for the purchase of injection equipment were estimated from data on the number of sterile injection equipment packs provided through pharmacies and average client out-of-pocket cost for these packs. However, indirect healthcare costs were not included in the analyses. All costs were estimated in 2008 Australian dollars and inflated to 2010 Australian dollars using the health consumer price index [22] . The annual healthcare costs per person are summarized in the Appendix, http:// links.lww.com/QAD/A245.
Cost-utility analysis was performed to compare the costs and outcomes between the counterfactual no-NSP scenario and the status quo. Health state utilities were used to adjust the absolute life expectancy to derive quality-adjusted life years (QALYs) [23, 24] . Healthcare costs were also calculated based on the number of people in each health state. The incremental cost-effectiveness ratio (ICER), expressed as cost per QALY gained, is the difference in costs between the counterfactual no-NSP scenario (HIV and HCV healthcare costs) and the status quo (NSP costs along with HIV and HCV healthcare costs) divided by the difference in QALYs between the same two scenarios. Analyses were performed for two time frames: 2000-2010 to study the return obtained over the period of investment, and 2010-2100 to examine the lifetime costs and consequences for the population related to the investment over the period 2000-2010. Costs were adjusted by an annual rate of 3% for the past 10 years and then discounted over future time by three choices of rate: 0, 3 and 5% for sensitivity analysis.
Calibration, uncertainties and sensitivity analysis The model was calibrated using a Bayesian melding procedure [25] parameter were derived from empirical data. These were used to define cumulative distribution functions (CDFs) for each model parameter (i.e., the priors). CDFs for each prevalence data point were defined similarly. A total of 1000 simulations were conducted, with parameter values chosen randomly based on the parameters' inverse CDFs. The likelihood, as a measure of goodness-of-fit, of each simulation was defined as the product of the likelihood of each parameter value and the likelihood of each prevalence point, as defined by their respective CDFs. The posterior parameter distribution was obtained by randomly sampling 1000 times over the original simulations, with each simulation weighted by its likelihood. This resulted in 100 unique simulations being used for the final analysis. The values and interquartile ranges (IQRs) quoted in the remainder of the article are derived from this posterior distribution of simulations.
For sensitivity analysis, partial rank correlation coefficients (PRCCs) were calculated between incidence in 2010 and the sampled model parameters. All simulations and analyses were performed in MATLAB 2010a (The Mathworks, Natick, Massachusetts, USA).
Results
The distribution of syringes, modeled HIV prevalence was relatively low and stable, reaching 1.1%, with IQR of 1.0-1.3% in 2010 (Fig. 3a) . The model also matched HCV prevalence, which changed over time between 50 and 60% (Fig. 4a) .
The model estimated substantial increases in both HIV and HCV infections according to the counterfactual assumptions in the absence of NSPs (with RSS levels between 25 and 50% Our sensitivity analysis revealed that the transmission probability per injecting episode using a contaminated syringe is the most important biological factor in determining both HIV and HCV incidence (PRCC: 0.78 for HIV and 0.60 for HCV), whereas the RSS level was the most sensitive behavioral factor (PRCC: 0.62 for HIV and 0.42 for HCV), followed by the frequency of injecting (PRCC: 0.51 for HIVand 0.27 for HCV). A full listing of parameter sensitivities is provided in the Appendix, http://links.lww.com/QAD/A245.
Discussion
In this study, we evaluated the cost-effectiveness of syringe distribution in Australia, a country in which NSPs have been well established for over two decades. Using available biological, behavioral and program data in a mathematical modeling framework, we showed that NSPs are likely to have averted a substantial number of HIV and HCV infections.
Importantly, our evaluation suggests that NSPs have facilitated consistently low prevalence of HIV among IDUs in Australia. In many other regions of the world, HIV prevalence is very high among IDUs [26] . In contrast to their success in preventing an epidemic of HIV among IDUs, NSPs have not effectively controlled HCV in Australia. This is likely due to greater biological transmissibility of HCV compared with HIV [27] and that HCV was already well established in the Australian IDU population before NSPs were introduced [28] . Despite high NSP coverage in Australia, RSS is still relatively common among new IDUs and has been demonstrated to be strongly associated with increased risk of HCV infection [29] .
In 2002, a cost-effectiveness analysis of the effect of NSPs in preventing HIV and HCV transmission among Australian IDUs was conducted to assess impact over the period 1991-2000 [30] . It was estimated that around 25 000 HIV and 21 000 HCV infections were prevented, with a net cost saving of A$20 million. In a recent report [8] we estimated that greater numbers of infections and healthcare costs would be saved according to less conservative assumptions regarding the counterfactual RSS. [31] . The studies all concluded that NSPs were cost saving or cost-effective compared to the lifetime cost of HIV.
Representatives from all Australian jurisdictions were asked to provide the costs of NSPs for this analysis that related only to NSPs, but this was not always possible. It should also be noted that there are only small changes in some outcomes over the period 2000-2010, such as number of people who receive ART, develop hepatocellular carcinoma or liver failure and receive liver transplantation. The benefits in these outcomes become more marked over a long period as infections averted lead to aversions of these clinical and disease-related outcomes.
Although the assumptions of this analysis were based on the best available data, these data consisted of nonrandom samples and case notifications. This study was limited by reliance on self-reports of behavior from serial crosssectional surveillance studies, which were based on selfadministered questionnaires. Self-administration of surveys has been shown to reduce social desirability bias but is still not an ideal measure of actual risk [32] [33] [34] . Where possible, multiple prospective observational studies using varied methods and sampling techniques were also considered. The most crucial component of our analysis was the counterfactual assumption in the absence of NSPs. Studies conducted prior to the introduction of NSPs could not be used for this analysis due to their use of incomparable survey questions, however, the 70-90% levels of RSS reported in these studies provides an indication of high pre-NSP RSS levels in Australia.
International studies provide some support for our counterfactual scenario [35] [36] [37] . Canada RSS recently increased from 10 to 23% following the closure of the only fixed NSP in the city of Victoria, but there was no change in RSS in Vancouver where NSPs remained open [38] .
Although we incorporated uncertainty in parameter estimates where possible, many of the differences that exist between IDUs could not be captured in this population-based mathematical model. Our model did not include large heterogeneity, such as distinguishing current and former IDUs, and used weighted averages across the distributions of injecting frequencies. We believe the population-based model used in the current analysis is most appropriate for the data available and represents an advance over previous models of HIV and HCV among IDUs in Australia.
This study used single estimates of HIV and HCV healthcare costs based on national medical benefits schemes. Ranges in utility weights were used to calculate uncertainties in QALYs. Conservatively, the model did not consider the increases in HCV costs that are likely to occur in the future associated with direct-acting antiviral therapy. As it is unlikely that HCV prevalence will decrease substantially over the next 10 years due to the impact of improved HCV treatment unless uptake is enormously enhanced, the increase in the costs should not affect the conclusions related to the cost-effectiveness of prevention programs.
Our model did not consider the reduction of RSS due to opioid substitution therapy, which has been associated with reductions in opiate use, mortality and the transmission of HIV [39] . However, as opioid substitution therapy is not an effective treatment for people who inject drugs other than opiates, its potential impact depends on the proportion of IDUs who inject opioids. During the period 2006-2010 in Australia, approximately 30% of IDUs injected opioids [4] . Studies have also shown that HCV transmission can be reduced when NSPs and opioid substitution therapy are delivered in combination [40] .
Although NSPs in Australia are effective, there is also a need for a range of complementary evidence-based public health responses to further prevent HIV and HCV transmission among IDUs. These include biomedical and behavioral prevention interventions which target injecting risk behaviors, and interventions designed to increase access to and early uptake of HCV treatment. In conclusion, our study provides evidence that the ongoing implementation of NSPs in Australia has led to substantial public health benefits and cost savings.
